MedTrace Logo

IVIG in Patients With Severe COVID-19 Requiring Mechanical Ventilation

NCT04616001 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2020-11-04

No results posted yet for this study

Summary

The purpose of this Pilot Study is to establish a hypothesis of whether or not intravenous immunoglobulin (IVIG) may impact the hospital length of stay, if started within 48 of mechanical ventilation in patients infected with SARS-CoV-2 virus.

Conditions

  • Covid19
  • SARS-CoV Infection

Interventions

DRUG

IVIG

Patients will receive IVIG daily for four days.

Sponsors & Collaborators

  • Sharp HealthCare

    lead OTHER

Principal Investigators

  • George Sakoulas, MD · Sharp HealthCare

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-01
Primary Completion
2021-06-30
Completion
2021-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04616001 on ClinicalTrials.gov